Ether

Ether

SCHEMBL3140342

CCOCC.COCCBr.[Ni]

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ether SCHEMBL2991328 0.97 ALDH1A1 (0.35) ALDH1A1
SCHEMBL20668551 0.85
SCHEMBL14127152 0.82
SCHEMBL5316 0.82
Ether SCHEMBL8961469 0.79 ALDH1A1 (0.38) ALDH1A1
Butane SCHEMBL2121237 0.79
Bromide SCHEMBL25315220 0.78
SCHEMBL15741725 0.78
Ether SCHEMBL703912 0.78 ALDH1A1 (0.42) ALDH1A1
Phosphine SCHEMBL4322491 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007140525-A1 A METHOD OF TREATMENT AND PROPHYLAXIS OF EVENTS, CONDITIONS AND DISEASES OF THE SYSTEMIC VASCULATURE AN IMMUNE FUNCTION TO DECREASE CARDIOVASCULAR RISK AND PATHOGENIC INFECTION HOENIG MICHEL (AU) 2007-12-13 WO claimed
US-20230392039-A1 COMPOUND, METHOD FOR PRODUCING COMPOUND, AND METHOD FOR PRODUCING SURFACE TREATMENT AGENT AGC Inc. (JP) 2023-12-07 US disclosed
US-20230226807-A1 Polymer Composites and Methods of Making the Same TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2023-07-20 US disclosed
WO-2023088965-A1 METHOD FOR THE SYNTHESIS OF A METAL CATALYST SURROUNDED WITH A CARBON MATRIX INSTITUT POLYTECHNIQUE DE GRENOBLE (FR) 2023-05-25 WO disclosed
EP-4184620-A1 METHOD FOR THE SYNTHESIS OF A METAL CATALYST SURROUNDED WITH A CARBON MATRIX Institut Polytechnique de Grenoble (FR) 2023-05-24 EP disclosed
US-20230023066-A1 N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME CORP. (US) 2023-01-26 US disclosed
WO-2021226424-A1 POLYMER COMPOSITES AND METHODS OF MAKING THE SAME TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-11-11 WO disclosed
EP-3436537-B1 ANAEROBICALLY CURABLE (METH)ACRYLATE COMPOSITIONS Henkel IP & Holding GmbH (DE) 2021-09-29 EP disclosed
US-11111416-B2 Anaerobically curable (meth)acrylate compositions Henkel IP & Holding GmbH (DE) 2021-09-07 US disclosed
US-11091504-B2 Process for the preparation of tavaborole, its novel polymorphic forms and the polymorphs thereof BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) 2021-08-17 US disclosed
US-20150336862-A1 CATALYTIC HYDROGENATION USING COMPLEXES OF BASE METALS WITH TRIDENTATE LIGANDS LOS ALAMOS NATIONAL SECURITY, LLC (US) 2015-11-26 US disclosed
US-20140303404-A1 NICKEL MODIFIED CATALYST FOR THE PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS EASTMAN CHEMICAL COMPANY (US) 2014-10-09 US disclosed
US-8785697-B2 Nickel modified catalyst for the production of hydroxy ether hydrocarbons by vapor phase hydrogenolysis of cyclic acetals and ketals EASTMAN CHEMICAL COMPANY (US) 2014-07-22 US disclosed
WO-2013041106-A1 SYSTEM PROVIDING CONTROLLED DELIVERY OF GASEOUS 11CO FOR CARBONYLATION REACTIONS IN THE PREPARATION OF RADIOPHARMACEUTICALS FOR PET IMAGING AARHUS UNIVERSITET (DK) 2013-03-28 WO disclosed
US-20120330068-A1 NICKEL MODIFIED CATALYST FOR THE PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS EASTMAN CHEMICAL COMPANY (US) 2012-12-27 US disclosed
US-8293938-B2 Alkylphosphonous acids, salts and esters, methods for the production thereof, and use of the same CLARIANT FINANCE (BVI) LIMITED (VG) 2012-10-23 US disclosed
US-8278243-B2 Laser imaging DATALASE LTD. (GB) 2012-10-02 US disclosed
WO-2012079583-A1 SYSTEM PROVIDING CONTROLLED DELIVERY OF GASEOUS CO FOR CARBONYLATION REACTIONS AARHUS UNIVERSITET (DK) 2012-06-21 WO disclosed
US-20100075848-A1 Laser Imaging DATALASE LTD. (GB) 2010-03-25 US disclosed
WO-2007140525-A1 A METHOD OF TREATMENT AND PROPHYLAXIS OF EVENTS, CONDITIONS AND DISEASES OF THE SYSTEMIC VASCULATURE AN IMMUNE FUNCTION TO DECREASE CARDIOVASCULAR RISK AND PATHOGENIC INFECTION HOENIG MICHEL (AU) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120330068-A1 NICKEL MODIFIED CATALYST FOR THE PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS KAT5, HRH3, KAT8 ALDH1A1 2375/4885
US-20230392039-A1 COMPOUND, METHOD FOR PRODUCING COMPOUND, AND METHOD FOR PRODUCING SURFACE TREATMENT AGENT SGMS2, SGMS1, BMP2 ALDH1A1 2261/4885
US-11091504-B2 Process for the preparation of tavaborole, its novel polymorphic forms and the polymorphs thereof HLA-B, VKORC1L1, VPS4B ALDH1A1 1902/4885
US-20230023066-A1 N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF LRRK2, CLK2, PARK7 ALDH1A1 4080/4885
US-20140303404-A1 NICKEL MODIFIED CATALYST FOR THE PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS KAT5, HRH3, KAT8 ALDH1A1 2375/4885
US-20150336862-A1 CATALYTIC HYDROGENATION USING COMPLEXES OF BASE METALS WITH TRIDENTATE LIGANDS HRH4, HRH3, CHD4 ALDH1A1 4343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.